公开(公告)号：US20060089311A1

公开(公告)日：2006-04-27

申请号：US10496758

申请日：2002-10-03

申请人： Deno Dialvnas ,  Aaron Scalia ,  John Lucas ,  Kristen Briggs

发明人： Deno Dialvnas ,  Aaron Scalia ,  John Lucas ,  Kristen Briggs

IPC分类号： A61K38/06

CPC分类号： A61K38/177 ,  G01N33/566 ,  G01N33/6893 ,  G01N2333/70575 ,  G01N2333/70578 ,  G01N2500/00 ,  G01N2800/042

摘要： The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of RYZN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

摘要翻译： 本发明涉及代谢研究领域，特别涉及有效减少体重并可用于治疗与肥胖有关的疾病和病症的化合物的发现。 预期通过本发明的方法治疗的肥胖相关疾病或病症包括但不限于高脂血症，动脉粥样硬化，胰岛素抵抗，糖尿病和高血压。 特别地，本发明提供了鉴定和使用RYZN活性的AGONISTS和ANTAGONISTS的方法，其中所述活性选自脂质分配，脂质代谢和胰岛素样活性。